3381 related articles for article (PubMed ID: 7296552)
1. Effect of 4'-doxorubicin analogs on heterotransplantation of human tumors in congenitally athymic mice.
Giuliani FC; Coirin AK; Rice MR; Kaplan NO
Cancer Treat Rep; 1981; 65(11-12):1063-75. PubMed ID: 7296552
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic response of human tumor xenografts in athymic mice to doxorubicin.
Giuliani FC; Zirvi KA; Kaplan NO
Cancer Res; 1981 Jan; 41(1):325-35. PubMed ID: 7448772
[TBL] [Abstract][Full Text] [Related]
3. New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse.
Giuliani FC; Kaplan NO
Cancer Res; 1980 Dec; 40(12):4682-7. PubMed ID: 7438099
[TBL] [Abstract][Full Text] [Related]
4. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
[TBL] [Abstract][Full Text] [Related]
5. Activity of bis-carbamoyloxymethyl derivatives of pyrroles and pyrrolizines against human tumor xenografts in nude mice.
Anderson WK
Cancer Res; 1982 Jun; 42(6):2168-70. PubMed ID: 6280852
[TBL] [Abstract][Full Text] [Related]
6. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors.
Li C; Price JE; Milas L; Hunter NR; Ke S; Yu DF; Charnsangavej C; Wallace S
Clin Cancer Res; 1999 Apr; 5(4):891-7. PubMed ID: 10213226
[TBL] [Abstract][Full Text] [Related]
8. Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas.
Fodstad O; Aamdal S; Pihl A; Boyd MR
Cancer Res; 1985 Apr; 45(4):1778-86. PubMed ID: 3978640
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
Geiger T; Müller M; Monia BP; Fabbro D
Clin Cancer Res; 1997 Jul; 3(7):1179-85. PubMed ID: 9815797
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity and pharmacokinetics of estra-1,3,5 (10)-triene-3,17 beta-diol, 3-benzoate, 17-((4-(4-bis(2-chloroethyl)amino)phenyl)-1-oxobutoxy) acetate) (Bestrabucil) in human tumor xenografts serially transplanted into nude mice.
Kubota T; Kawamura E; Suzuki T; Yamada T; Toyoda H; Miyagawa T; Kurokawa T
Jpn J Clin Oncol; 1986 Dec; 16(4):357-64. PubMed ID: 3795532
[TBL] [Abstract][Full Text] [Related]
11. Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts.
Pratesi G; De Cesare M; Caserini C; Perego P; Dal Bo L; Polizzi D; Supino R; Bigioni M; Manzini S; Iafrate E; Salvatore C; Casazza A; Arcamone F; Zunino F
Clin Cancer Res; 1998 Nov; 4(11):2833-9. PubMed ID: 9829750
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer.
Utsugi T; Shibata J; Sugimoto Y; Aoyagi K; Wierzba K; Kobunai T; Terada T; Oh-hara T; Tsuruo T; Yamada Y
Cancer Res; 1996 Jun; 56(12):2809-14. PubMed ID: 8665518
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH
Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436
[TBL] [Abstract][Full Text] [Related]
15. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of kigamicin D on mouse tumor models.
Masuda T; Ohba S; Kawada M; Osono M; Ikeda D; Esumi H; Kunimoto S
J Antibiot (Tokyo); 2006 Apr; 59(4):209-14. PubMed ID: 16830887
[TBL] [Abstract][Full Text] [Related]
17. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
19. Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation.
Chen CT; Gan Y; Au JL; Wientjes MG
Cancer Res; 1998 Jul; 58(13):2777-83. PubMed ID: 9661891
[TBL] [Abstract][Full Text] [Related]
20. Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin.
Ravel D; Dubois V; Quinonero J; Meyer-Losic F; Delord J; Rochaix P; Nicolazzi C; Ribes F; Mazerolles C; Assouly E; Vialatte K; Hor I; Kearsey J; Trouet A
Clin Cancer Res; 2008 Feb; 14(4):1258-65. PubMed ID: 18281561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]